Beam therapeutics announces new data from beacon phase 1/2 clinical trial of beam-101 in sickle cell disease at american society of hematology (ash) annual meeting

All seven patients treated with beam-101 achieved hemoglobin f (hbf) induction of >60%, hemoglobin s (hbs) reduction to
ASH Ratings Summary
ASH Quant Ranking